Natco Pharma has announced that it will host an earnings call with investors and analysts on Friday, August 14, 2026 at 17:30 IST to discuss the company's unaudited financial results for the first quarter of FY27 (Q1FY27), for the quarter ended June 30, 2026. The call is being organised by 360 ONE Capital Market Private Limited as part of India Equity Research coverage.

Management Participants

The following senior executives will represent Natco Pharma on the earnings call:

• Mr. Rajeev Nannapaneni – Vice-Chairman and CEO
• Mr. Rajesh Chebiyam – Executive Vice President, Crop Health Sciences
• Mr. Amit Parekh – Chief Financial Officer (CFO)
• Mr. Rajeev Menon – Lead, IR

Earnings Call Details

The key details of the conference call are summarised below:

Conference Dial-In Numbers

Participants can join the call using the following international dial-in numbers:

How to Join

Participants may also register via the Express Join with Diamond Pass™ link for seamless access to the call. For further information, investors and analysts may contact Mr. Rohit Bhat at rohit.bhat@360.one . The disclosure was made by Ch. Venkat Ramesh, Company Secretary and Compliance Officer of Natco Pharma, on August 11, 2026.

Natco Pharma will hold a meeting of its Board of Directors on August 14, 2026, to consider and evaluate proposals for raising funds through the issuance of equity shares or other securities. The potential fundraising methods include public issues, preferential issues, rights issues, private placements, qualified institutions placements, or any combination thereof, subject to market conditions and necessary regulatory approvals.

The intimation was issued pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. This notice serves as an update to an earlier intimation dated August 6, 2026, regarding the scheduling of the board meeting.

Fundraising Options Under Consideration

The Board is evaluating multiple avenues for capital raising. The specific instruments under consideration are detailed below:

Any decision to proceed with these measures will be subject to prevailing market conditions and the receipt of all required regulatory, statutory, and other approvals as mandated by applicable laws.

Compliance and Disclosure

Ch. Venkat Ramesh, Company Secretary & Compliance Officer of Natco Pharma Limited, signed the intimation letter dated August 11, 2026. The company has submitted this disclosure to both the BSE Limited and the National Stock Exchange of India Limited for record-keeping purposes, in compliance with listing obligations.